Design and Implementation of a Randomized Crossover Study of Valproic Acid and Antiretroviral Therapy to Reduce the HIV Reservoir

HIV Clinical Trials

Volumn 13, Issue 6, 2012, Pages 301-307

  Routy, J ^a,b   Angel, J ^c,d   Spaans, J ^d   Trottier, B ^e   Rouleau, D ^c   Baril, J ^f   Harris, M ^g   Trottier, S ^h   Singer, J ⁱ   Chomont, N ^j   Sekaly R ^f,j   Tremblay, C ^f  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^e Clinique Medicale l'Actuel   (Canada)

^f CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h LAVAL UNIVERSITY   (Canada)

ⁱ Canadian HIV Trials Network   (Canada)

^j VGTI Florida   (United States)

more..

Author keywords

crossover study design; HIV eradication; HIV reservoirs; valproic acid

Indexed keywords

ANTIRETROVIRUS AGENT; VALPROIC ACID;

ARTICLE; CROSSOVER PROCEDURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN; TREATMENT DURATION;

ANTI-HIV AGENTS; CROSS-OVER STUDIES; HIV; HIV INFECTIONS; HUMANS; RESEARCH DESIGN; VALPROIC ACID;

EID: 84870582646     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1306-301     Document Type: Article

References (26)

1. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA. 1997; 94:13193-13197 (Pubitemid 27518498)
2. Finzi D, Hermankova M, Pierson T, et al. Identifi cation of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278:1295-1300 (Pubitemid 27495742)
3. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection. Proc Natl Acad Sci USA. 1998;95:8869-8873 (Pubitemid 28350581)
4. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1 even in patients on effective combination therapy. Nat Med. 1999;5:512-517 (Pubitemid 29220209)
5. Sheridan PL, Mayall TP, Verdin E, Jones KA. Histone acetyltransferases regulate HIV-1 enhancer activity in vitro. Genes Dev. 1997;11:3327-3340 (Pubitemid 28023957)
6. Benkirane M, Chun RF, Xiao H, et al. Activation of integrated provirus requires histone acetyltransferase. p300 and P/CAF are coactivators for HIV-1 Tat. J Biol Chem. 1998;273:24898-24905 (Pubitemid 28454997)
7. Ylisastigui L, Coull JJ, Rucker VC, et al. Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors. J Infect Dis. 2004;190:1429-1437 (Pubitemid 39332182)
8. Lehrman G, Hogue IB, Palmer S, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet. 2005;366:549-555 (Pubitemid 41140329)
9. Archin NA, Eron JJ, Palmer S, et al. Standard ART and valproic acid have limited impact on the persistence of HIV infection in resting CD4+ T cells. AIDS. 2008;22:1131-1135
10. Sagot-Lerolle N, Lamine A, Chaix ML et al. Prolonged valproic acid treatment does not reduce the size of the latent HIV reservoir. AIDS. 2008;22:1125-1129
11. Routy JP, Tremblay CL, Angel JB, et al. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med. 2012;13(5):291-296
12. Louis TA, Lavori PW, Bailar JC, Polansky M. Crossover and self-controlled designs in clinical research. New Engl J Med. 1984;310(1):24-31 (Pubitemid 14212477)
13. Young JM, Florkowski CM, Molyneux SL, et al. A randomized, double-blind, placebo-controlled crossover study of coenzyme Q(10) therapy in hypertensive patients with the metabolic syndrome. Am J Hypertension. 2011;25(2):261-270
14. Dashti-Khavidaki S, Chamani N, Khalili H, et al. Comparing effects of clonazopam and zolpidem on sleep quality of patients on maintenance hemodialysis. Iran J Kidney Dis. 2011;5(6):404-409
15. Samineni D, Desai PB, Sallans L, Fichtenbaum CJ. Steadystate pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin. Clin Pharmacol. 2012;52(6):922-931
16. Innes S, Norman J, Smith P, et al. Bioequivalence of dispersed stavudine: opened versus closed capsule dosing. Antivir Ther. 2011;16(7):1131-1134
17. Johnston C, Saracino M, Kuntz S, et al. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomized, open-label, cross-over trials. Lancet. 2012;379 (9816):641-647
18. Mugwanya K, Baeten JM, Mugo NR. High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial. J Infect Dis. 2011;204(12):1912-1917
19. Nguyen A, Calmy A, Delhumeau C, et al. A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). AIDS. 2011;25(12):1481-1487
20. Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confi rm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003;9:727-728 (Pubitemid 36749221)
21. Jones B, Kenward MG, eds. Design and Analysis of Cross-Over Trials (chap. 2). London: Chapman and Hall; 1989
22. Woods JR, Williams JG, Tavel M. The two-period crossover design in medical research. Ann Intern Med. 1989;110(7):560-566 (Pubitemid 19097323)
23. Emery S, Capra WB, Cooper DA, et al. Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodefi ciency virus type 1 disease. J Infect Dis. 2000;182:428-434 (Pubitemid 30651038)
24. Dybul M, Hidalgo B, Chun TW, et al. Pilot study of the effects of intermittent interleukin-2 on human immunodefi ciency virus (HIV)-specifi c immune responses in patients treated during recently acquired HIV infection. J Infect Dis. 2002;185:61-68 (Pubitemid 34043017)
25. Hills M, Armitage P. The two-period cross-over clinical trial. Br J Clin Pharmacol. 1979;8:7-20 (Pubitemid 9234327)
26. Rasmussen T, Søgaard O, Melchjorsen J, et al. The histone deacetylase inhibitor (HDACi) panobinostat (LBH589) stimulates HIV-1 expression more potently than other HDACi in clinical use and disrupts HIV latency at clinically achievable concentrations (Paper 370). Presented at: the 20th Conference on Retroviruses and Opportunistic Infections; March 5-8, 2012; Seattle, Washington.